Furthermore, compared with placebo, liraglutide treatment decreased leptin by 20% and liver fat content by 44%, thus supporting a specific effect on hepatic ectopic fat
The pharmaceutical version will not be available until after FDA approval
Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z
Neumiller, Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
*Correspondence: Zheer Kejlberg Al-Mashhadi, [email protected] This article was submitted to Clinical Diabetes, a section of the journal Frontiers in Endocrinology Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
Data on income in the matched cohort (italicized) are presented without imputations